Skip to main content

Table 2 The clinical parameter of the effects of inhaled GM-CSF during the 6 months treatment periods

From: Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

  3 months 6 months
  Control group (n = 17) Treatment group (n = 17) P value Control group (n = 13) Treatment group (n = 17) P value
ΔA-aDO2 (mmHg) 0.51 ± 12.09 −0.35 ± 13.76 0.848 1.85 ± 11.21 7.31 ± 8.81 0.146
A-aDO2 (mmHg) 27.81 ± 11.04 28.79 ± 10.19 0.794 25.69 ± 11.70 22.31 ± 7.45 0.342
ΔPaO2 (mmHg) 0.92 ± 10.34 0.62 ± 12.07 0.94 2.95 ± 10.34 7.26 ± 10.29 0.267
PaO2 (mmHg) 78.42 ± 10.74 78.37 ± 10.17 0.988 82.42 ± 9.71 83.84 ± 8.57 0.589
FVC pred (%) 77.24 ± 14.91 78.48 ± 13.72 0.801 80.41 ± 15.60 77.34 ± 23.32 0.688
TLC pred (%) 74.09 ± 11.37 73.12 ± 15.29 0.836 74.28 ± 11.18 78.48 ± 8.88 0.269
DLCO pred (%) 67.12 ± 14.72 69.19 ± 19.83 0.732 70.83 ± 14.62 74.91 ± 14.80 0.465
DLCO/VA pred (%) 95.67 ± 17.32 98.71 ± 21.03 0.641 98.92 ± 12.47 95.93 ± 15.44 0.577
SGRQ symptom 24.84 ± 17.33 24.22 ± 23.32 0.521 29.50 ± 18.61 18.47 ± 19.29 0.097
SGRQ activity 33.45 ± 19.35 24.31 ± 18.92 0.173 28.98 ± 18.78 19.41 ± 17.10 0.149
SGRQ effect 16.38 ± 15.94 17.11 ± 17.86 0.336 21.58 ± 17.60 9.29 ± 10.73 0.023
SGRQ total 14.76 ± 14.52 20.45 ± 17.55 0.285 25.11 ± 16.36 13.88 ± 10.91 0.030
6MWD 494.06 ± 75.43 496.41 ± 75.43 0.926 475.09 ± 85.31 501.13 ± 88.31 0.452
Mean lung density NA NA   − 739.64 ± 82.70 − 733.17 ± 61.41 0.804
Total lung volume (ml) NA NA   4485.71 ± 971.37 4365.67 ± 1322.58 0.808
Hb (g/dL) 15.42 ± 1.53 15.34 ± 1.42 0.863 15.65 ± 1.79 15.70 ± 1.60 0.932
HCT (%) 44.35 ± 3.54 44.52 ± 3.48 0.881 45.10 ± 4.04 45.50 ± 4.46 0.792
LDH (U/L) 226.88 ± 46.22 223.86 ± 59.32 0.867 230.36 ± 28.96 203.38 ± 60.36 0.130
CEA (U/L) 3.72 ± 3.31 4.87 ± 3.68 0.619 4.40 ± 2.25 3.14 ± 1.74 0.076
  1. Abbreviations: See Table 1